BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frayle H, Gori S, Rizzi M, Graziani BN, Vian E, Giorgi Rossi P, Del Mistro A. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system. BMC Womens Health 2019;19:47. [PMID: 30909894 DOI: 10.1186/s12905-019-0743-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Li SW, Li W, Cai HB. Elastic Net-Based Identification of a Multigene Combination Predicting the Survival of Patients with Cervical Cancer. Med Sci Monit 2019;25:10105-13. [PMID: 31884508 DOI: 10.12659/MSM.918393] [Reference Citation Analysis]
2 Safaeian M, Wright TC Jr, Stoler MH, Ranger-Moore J, Rehm S, Aslam S, Fang Q, Volkir P, Ridder R. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Am J Obstet Gynecol 2021;225:278.e1-278.e16. [PMID: 33852886 DOI: 10.1016/j.ajog.2021.03.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Arbyn M, Simon M, Peeters E, Xu L, Meijer CJLM, Berkhof J, Cuschieri K, Bonde J, Ostrbenk Vanlencak A, Zhao FH, Rezhake R, Gultekin M, Dillner J, de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Wentzensen N, Poljak M. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect 2021;27:1083-95. [PMID: 33975008 DOI: 10.1016/j.cmi.2021.04.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Ejegod DM, Pedersen H, Pedersen BT, Jonassen CM, Lie AK, Hulleberg LS, Arbyn M, Bonde J. Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program. Am J Clin Pathol 2022;157:390-8. [PMID: 34546350 DOI: 10.1093/ajcp/aqab138] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sundström K, Lamin H, Dillner J. Validation of the cobas 6800 human papillomavirus test in primary cervical screening. PLoS One 2021;16:e0247291. [PMID: 33606755 DOI: 10.1371/journal.pone.0247291] [Reference Citation Analysis]
6 Weston G, Dombrowski C, Harvey MJ, Iftner T, Kyrgiou M, Founta C, Adams EJ. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. BMJ Open 2020;10:e031303. [PMID: 32152154 DOI: 10.1136/bmjopen-2019-031303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ejegod DM, Hansen M, Christiansen IK, Pedersen H, Quint W, Xu L, Arbyn M, Bonde J. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. J Clin Virol 2020;128:104336. [PMID: 32446166 DOI: 10.1016/j.jcv.2020.104336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Molina MA, Carosi Diatricch L, Castany Quintana M, Melchers WJ, Andralojc KM. Cervical cancer risk profiling: molecular biomarkers predicting the outcome of hrHPV infection. Expert Rev Mol Diagn 2020;20:1099-120. [PMID: 33044104 DOI: 10.1080/14737159.2020.1835472] [Reference Citation Analysis]